- Home
- UNB vs CRDF Comparison
UNB vs CRDF Comparison
Compare UNB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- CRDF
- Stock Information
- Founded
- UNB 1891
- CRDF 1999
- Country
- UNB United States
- CRDF United States
- Employees
- UNB N/A
- CRDF N/A
- Industry
- UNB Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNB Finance
- CRDF Health Care
- Exchange
- UNB Nasdaq
- CRDF Nasdaq
- Market Cap
- UNB 167.6M
- CRDF 195.6M
- IPO Year
- UNB 1998
- CRDF N/A
- Fundamental
- Price
- UNB $31.34
- CRDF $2.85
- Analyst Decision
- UNB
- CRDF Strong Buy
- Analyst Count
- UNB 0
- CRDF 4
- Target Price
- UNB N/A
- CRDF $12.00
- AVG Volume (30 Days)
- UNB 11.7K
- CRDF 1.6M
- Earning Date
- UNB 05-13-2025
- CRDF 05-01-2025
- Dividend Yield
- UNB 4.63%
- CRDF N/A
- EPS Growth
- UNB N/A
- CRDF N/A
- EPS
- UNB 1.92
- CRDF N/A
- Revenue
- UNB $47,157,000.00
- CRDF $683,000.00
- Revenue This Year
- UNB N/A
- CRDF N/A
- Revenue Next Year
- UNB N/A
- CRDF N/A
- P/E Ratio
- UNB $16.32
- CRDF N/A
- Revenue Growth
- UNB N/A
- CRDF 39.96
- 52 Week Low
- UNB $21.00
- CRDF $2.01
- 52 Week High
- UNB $37.70
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- UNB 58.70
- CRDF 41.85
- Support Level
- UNB $28.00
- CRDF $2.36
- Resistance Level
- UNB $29.32
- CRDF $3.04
- Average True Range (ATR)
- UNB 1.31
- CRDF 0.24
- MACD
- UNB 0.18
- CRDF 0.03
- Stochastic Oscillator
- UNB 78.91
- CRDF 56.98
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.